Arformoterol

Arformoterol
Systematic (IUPAC) name
	N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a602023
Licence data	US FDA:link
Pregnancy cat.	C(US)
Legal status	℞-only (US)
Routes	nebuliser
Pharmacokinetic data
Protein binding	52–65%
Half-life	26 hours
Identifiers
CAS number	67346-49-0
ATC code	None
PubChem	CID 3083544
DrugBank	DB01274
ChemSpider	2340731
UNII	F91H02EBWT
ChEBI	CHEBI:408174
ChEMBL	CHEMBL1201137
Chemical data
Formula	C19H24N2O4
Mol. mass	344.405 g/mol
	InChI InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 ; Key:BPZSYCZIITTYBL-YJYMSZOUSA-N ;
(what is this?) (verify);

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Arformoterol is a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.^[1]

It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

[edit] References

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.